A recent letter by Campochiaro et al. highlights the errors in our previous manuscript titled “Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases.” We like to thank Dr Campochiaro et al. for their comments and will address them individually in this letter.

  1. (1)

    Regarding the primary analysis of the Phase II LADDER trial, we thank the authors of the letter for pointing out that the Port Delivery System (PDS) 100 mg/ml arm had a median, not mean, refill time of 15.0 months.

  2. (2)

    During the submission of the manuscript on the 21 August 2019, the estimated completion date of the Phase III ARCHWAY trial (ClinicalTrials.gov NCT03677934) was stated as May 2022 on ClinicalTrials.gov. A revision of the completion date to April 2021 was submitted on 25 October 2019 [1] after manuscript submission (History of Changes for Study: NCT03677934).

  3. (3)

    The authors of the review understood that the PORTAL trial (ClinicalTrials.gov NCT03683251) is an extension of the LADDER or ARCHWAY trials.

  4. (4)

    We understand that the wording used by us was confusing with respect to the periodicity of refills. A more precise wording should have been used to highlight that participants receive refills every 24 weeks during the trial for up to 144 weeks instead of 24 week periodic refills.

  5. (5)

    Finally, during the submission of the manuscript, once again the estimated completion of the PORTAL extension trial was stated as June 2022 on ClinicalTrials.gov. However, a revision of the completion date to January 2022 was submitted on 25 October 2019 [2] after submission of our manuscript (History of Changes for Study: NCT03683251).

Regarding the primary analysis of the Phase II LADDER trial, we thank the authors of the letter for pointing out that the Port Delivery System (PDS) 100 mg/ml arm had a median, not mean, refill time of 15.0 months.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD